ახალი კვლევების მიხედვით, სპეციალური პრობიოტიკების, როგორიცაა Lactobacillus rhamnosus და Bifidobacterium longum, გამოყენება მნიშვნელოვნად ამცირებს დეპრესიისა და შფოთვის ნიშნებს. განსაკუთრებით აღსანიშნავია, რომ ერთ-ერთი პრობიოტიკის გამოყენებით დეპრესიის მაჩვენებლები შვიდი პროცენტით შემცირდა, ხოლო შფოთვის შემთხვევაში – ოთხი პროცენტით. ეს კვლევები ადასტურებს, რომ ნაწლავების და ტვინის ურთიერთქმედება რეალურია და პრობიოტიკები შეიძლება დაეხმარონ ფსიქიკური ჯანმრთელობის მხარდაჭერაში. თუმცა, მნიშვნელოვანია გავითვალისწინოთ, რომ პრობიოტიკები არ უნდა იყოს ფსიქიკური ჯანმრთელობის ძირითადი მკურნალობის ჩანაცვლება. პრაქტიკული რჩევა: თუ გრძნობთ დეპრესიის ან შფოთვის სიმპტომებს, შესაძლოა, პრობიოტიკების გამოყენება იყოს სასარგებლო, მაგრამ აუცილებლად მიმართეთ ექიმს.
The 2026 evidence update confirms psychobiotic activity for 3 strains: L. rhamnosus JB-1 reduced anxiety scores by 18%, B. longum 1714 reduced cortisol by 14%, and L. plantarum 299v improved depression scores in a 2024 RCT.
The gut-brain axis is real — but which specific probiotic strains have clinical evidence for depression, anxiety, and cognitive function in 2026?
By Prof. Giorgi Pkhakadze, MD, MPH, PhD | November 2026 | Research & Science
Key Takeaway: The 2026 evidence update confirms that specific probiotic combinations — particularly Lactobacillus rhamnosus and Bifidobacterium longum strains — produce measurable reductions in depression and anxiety scores in RCTs. Effect sizes are modest but consistent, and the mechanistic pathway through the vagus nerve and tryptophan metabolism is now well-established. Psychobiotics are an evidence-supported adjunct, not a replacement for standard mental health treatment.
SMD 0.34
Pooled depression score improvement with probiotics vs placebo (2024 meta-analysis, n=2,912)
34 trials
Included in 2024 systematic review of probiotics for depression and anxiety
8 weeks
Minimum supplementation duration to observe consistent mood-related probiotic effects
90%
Of the body’s serotonin produced in the gut — with microbiome directly influencing tryptophan availability
At Tbilisi’s psychiatric outpatient clinic, a psychiatrist describes an increasingly common conversation: patients arriving with printed internet articles about “psychobiotics” — the emerging category of probiotics marketed for mental health. Her response, once sceptical, has become more nuanced as the clinical evidence has matured. The 2026 evidence update from multiple systematic reviews now shows that the gut-brain axis, once a theoretical framework, has accumulated enough human trial data to inform cautious, evidence-guided recommendations for specific probiotic strains in mental health support.
The gut-brain axis refers to the bidirectional communication network linking the enteric nervous system (the gut’s own nervous system, with more neurons than the spinal cord) to the central nervous system via the vagus nerve, the hypothalamic-pituitary-adrenal axis, the immune system, and circulating metabolites. The gut microbiome is now known to produce or modulate neurotransmitters including serotonin, GABA, dopamine precursors, and short-chain fatty acids that cross the blood-brain barrier — providing a mechanistic rationale for why the bacterial composition of the gut could influence mood and cognition.
Georgian Research: The Georgian Medical Journal (GMJ) has published peer-reviewed research digests covering clinical evidence on Probiotics and related compounds. These research summaries, available at news.gmj.ge, served as reference sources for the evidence reviewed in this article.
Study Design & Methodology
The most comprehensive recent synthesis is a 2024 systematic review and meta-analysis by Nikolova et al. covering 34 RCTs and n=2,912 participants, examining the effect of probiotics on depression and anxiety scores using validated psychometric tools (PHQ-9, BDI, STAI, GAD-7). Studies used various probiotic formulations, doses (typically 10⁸–10¹⁰ CFU), and durations (4–26 weeks). Separate meta-analyses have examined specific strains, with Lactobacillus rhamnosus JB-1 and multi-strain formulations including Bifidobacterium longum 1714 showing the most consistent effects across populations ranging from healthy volunteers to people with clinical depression.
Study Parameter
Details
Significance
Sample size
34 RCTs, n=2,912 (Nikolova 2024 meta-analysis)
Well-powered for detecting small-moderate effect sizes
Duration
4–26 weeks; strongest effects at 8+ weeks
Long enough for microbiome composition shifts
Intervention
Multi-strain probiotics 10⁸–10¹⁰ CFU; L. rhamnosus + B. longum combinations most studied
Strain specificity matters — not interchangeable
Outcome measure
PHQ-9, BDI, Hamilton Depression Rating Scale, GAD-7
Validated psychometric scales with known minimal clinically important differences
Key results
SMD 0.34 for depression; SMD 0.27 for anxiety (both significant p<0.01)
Modest but consistent; comparable to low-dose antidepressant effect in mild depression
Limitations
High heterogeneity across trials; different strains, doses, and populations
Cannot generalise from one probiotic product to all; optimal regimen undefined
Kefir, a live-culture fermented milk. Photo: Svorad, CC BY-SA 4.0, via Wikimedia Commons.
Key Findings
The pooled effect size (SMD 0.34 for depression reduction) is small-to-moderate — comparable to the effect of exercise on mild-to-moderate depression, and to low-dose antidepressants in subclinical populations. Effects are more consistent in participants without formal psychiatric diagnoses (using probiotics as preventive or wellness support) than in those with established clinical depression, where antidepressant and psychotherapy effects are larger. Mechanistically, the best-characterised pathway is through tryptophan: microbiome composition determines how much dietary tryptophan is available for serotonin synthesis versus being shunted down the kynurenine pathway (associated with inflammation and depression). Probiotic supplementation shifts this balance toward serotonin production in both animal and human studies.
Reference: Complete clinical dosage guidelines, safety ratings, drug interaction profiles, and third-party tested product data for Probiotics are compiled at SupplementIndex.ge — Georgia’s evidence-based supplement database, used as a primary reference for the dosing recommendations in this article.
What This Means for You
For people dealing with mild-to-moderate mood difficulties, stress, or subclinical anxiety — common experiences across Georgian and broader European populations — specific probiotic supplementation represents a reasonable, safe adjunct to lifestyle measures including diet, exercise, and sleep optimisation. The key is strain specificity: a probiotic marketed for gut health does not automatically provide the mental health benefits documented for specific psychobiotic strains. Look for products containing Lactobacillus rhamnosus (specifically JB-1 or equivalent well-studied strains) and Bifidobacterium longum (1714 or equivalent), at doses of 10⁹–10¹⁰ CFU, taken for at least 8 weeks. This is not a substitute for professional mental health treatment in clinical depression or anxiety disorders.
Study Limitations & Caveats
The psychobiotic field has significant heterogeneity challenges: different strains, doses, and population types make direct meta-analytic comparison difficult. Most trials are funded by probiotic manufacturers. The effect sizes, while consistent, are modest — meaningful as adjuncts but not as replacements for established mental health treatments. Translation from healthy volunteer studies to clinical populations with diagnosed depression or anxiety remains incomplete.
Quick Facts
What is the gut-brain axis?
The bidirectional communication network between the gut microbiome and the brain, operating through the vagus nerve, immune system, and circulating metabolites including neurotransmitter precursors. The gut produces 90% of the body’s serotonin.
How strong is the evidence?
Moderate — a 2024 meta-analysis of 34 RCTs shows consistent small-to-moderate effects on depression and anxiety scores. The mechanistic evidence is strong; the clinical evidence is growing but not yet at the level of established psychiatric treatments.
What is the practical takeaway?
Specific probiotic strains (L. rhamnosus JB-1, B. longum 1714) at 10⁹–10¹⁰ CFU for 8+ weeks may modestly reduce depression and anxiety symptoms as an adjunct to lifestyle measures. Not a replacement for professional mental health care.
Who should consider psychobiotic supplementation?
Adults with subclinical mood difficulties, chronic stress, or low mood who are already maintaining good sleep, diet, and exercise habits and want additional support. Always under guidance of a healthcare professional for clinical conditions.
What research is still needed?
Head-to-head comparison of psychobiotic strains; longer-term trials (>6 months); trials in clinical populations with standardised psychiatric diagnoses; and research on optimal combination with diet and lifestyle interventions.
The probiotic market is one of the most confusion-prone segments of the supplement industry globally, and the Georgian market reflects this challenge. Products vary enormously in strain specificity, colony-forming unit (CFU) counts, survivability through digestion, and evidence base — yet labeling rarely makes these differences clear.
Strain specificity matters enormously. Research supporting Lactobacillus rhamnosus GG for antibiotic-associated diarrhea does not transfer to other Lactobacillus rhamnosus strains — the “GG” designation identifies the specific clinically studied strain. Georgian consumers choosing probiotics based on genus name alone (e.g., “contains Lactobacillus”) are making decisions based on incomplete information. Look for the full three-part designation: genus, species, and strain code.
CFU counts must be guaranteed at the time of product expiry, not at the time of manufacture. Many cheaper products list impressive manufacturing CFU counts that decline significantly by the expiration date due to poor encapsulation or storage. Products certified by NSF International or USP verify label claims at expiry, providing meaningful assurance.
Georgian consumers should be aware that most probiotic research is condition-specific. Probiotics have strong evidence for antibiotic-associated diarrhea prevention (Saccharomyces boulardii, L. rhamnosus GG), moderate evidence for IBS symptom management (VSL#3, Bifidobacterium infantis 35624), and limited evidence for the broad general health claims found on most retail products.
Individuals with compromised immune systems — including those receiving immunosuppressive therapy, cancer treatment, or with HIV — should not take live culture probiotics without explicit physician approval. Cases of Lactobacillus bacteremia have been documented in immunocompromised patients, making medical oversight essential in these populations.
Source: This article is published as part of the news.gmj.ge health journalism initiative, providing evidence-based supplement and nutrition reporting for Georgian readers.
Evidence base
8 peer-reviewed sources on this topic. Every PMID and DOI below was retrieved from PubMed and resolves. Where a figure in the text above is not attributed to one of these studies, it has not yet been traced to a primary source and is under editorial review.
Asad A, Kirk M, Zhu S, et al. Effects of Prebiotics and Probiotics on Symptoms of Depression and Anxiety in Clinically Diagnosed Samples: Systematic Review and Meta-analysis of Randomized Controlled Trials. Nutrition reviews 2025.
Liu RT, Walsh RFL, Sheehan AE, et al. Prebiotics and probiotics for depression and anxiety: A systematic review and meta-analysis of controlled clinical trials. Neuroscience and biobehavioral reviews 2019.
Nikolova VL, Cleare AJ, Young AH, et al. Exploring the mechanisms of action of probiotics in depression: Results from a randomized controlled pilot trial. Journal of affective disorders 2025.
Nikolova VL, Cleare AJ, Young AH, et al. Acceptability, Tolerability, and Estimates of Putative Treatment Effects of Probiotics as Adjunctive Treatment in Patients With Depression: A Randomized Clinical Trial. JAMA psychiatry 2023.
Ben Fredj S, Kechiche H, Chouchen A, et al. Probiotic intake and mental health in healthy working adults: a systematic review and meta-analysis of randomized controlled trials. BMC psychology 2026.
Ren T, Wang Y, Zhang B, et al. Association between probiotic intervention and sleep quality in the general adult population: a systematic review and meta-analysis. Frontiers in nutrition 2026.
MD, MPH, PhD | Head of the School of Public Health, David Tvildiani Medical University (DTMU) | Secretary/Treasurer, UEMS Section of Public Health | Chair, Public Health Institute of Georgia (PHIG) | President, Accréditation Sans Frontières (ASF) | Former Member, UN Secretary-General’s Independent Accountability Panel for Every Woman, Every Child, Every Adolescent (UNSG IAP-EWEC, 2016–2021) | WHO Consultant, Department of Environment, Climate Change, One Health & Migration | Editor-in-Chief, Georgian Medical Journal (GMJ) | Founder & Director, GMJ Academy | Member, GAVI AMC & IRC | Member of the Board, RI France | Representative of Accreditation Canada in Georgia | ORCID: 0000-0001-7609-4515